Characteristics of RA -patients identified in the Swedish Rheumatology Quality Register (SRQ), at baseline, 3-month and 6-month follow-up visit*
| Patients with complete information at 3-month follow-up visit (n=4 831) | Patients with complete information at 6-month follow-up visit (n=4 010) | |||
|---|---|---|---|---|
| Baseline | 3-Month follow-up | Baseline | 6-Month follow-up | |
| Methotrexate | 4 831 (100) | 4 497 (93) | 4 010 (100) | 3 579 (89) |
| Prednisolone | 3 144 (65) | 2 984 (62) | 2 604 (65) | 2 311 (58) |
| Response status† | ||||
| Non-responders | 1 382 (29) | 1 576 (39) | ||
| Moderate responders | 1 284 (27) | 776 (19) | ||
| Good responders | 2 165 (45) | 1 658 (41) | ||
*Values are the number (%).
†Response status according to EULAR response criteria. If change of DMARD at follow-up visit=non-responder.
RA, rheumatoid arthritis.